Clinical Trial Update: Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial update evaluating mitomycin C–based HIPEC for hepatocellular carcinoma with peritoneal metastasis following srHCC, with unclear statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Peritoneal Metastasis

Drugs mentioned

• Mitomycin C–based HIPEC (mitomycin C)

Snippet

Sponsor: West China Hospital | Conditions: Hepatocellular Carcinoma, Peritoneal Metastasis | Phase 2, Phase 3 | Status: UNKNOWN